To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04003610
Title Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | SVK | ROU | POL | ITA | IRL | GBR | FRA | FIN | ESP | DEU | CAN | BEL | AUT